miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS - PubMed (original) (raw)
. 2011 Apr;350(1-2):207-13.
doi: 10.1007/s11010-010-0700-6. Epub 2011 Jan 1.
Xiaobing Niu, Xiangxiang Zhang, Jun Tao, Deyao Wu, Zidun Wang, Pengchao Li, Wei Zhang, Hongfei Wu, Ninghan Feng, Zengjun Wang, Lixin Hua, Xinru Wang
Affiliations
- PMID: 21197560
- DOI: 10.1007/s11010-010-0700-6
miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS
Bin Xu et al. Mol Cell Biochem. 2011 Apr.
Abstract
MicroRNAs have been implicated in regulating diverse cellular pathways. Emerging evidence indicates that miR-143 plays causal roles in cancer tumorigenesis as a tumor suppress gene; however, its role in prostate cancer tumorigenesis remains largely unknown. The aims of this study were to verify the effect of miR-143 on proliferation and migration abilities of prostate cancer cells. The expression level of miR-143 and its target gene KRAS were measured by realtime PCR and western blotting, respectively. Effects of miR-143 in cell proliferation, migration and chemosensitivity were evaluated by MTT assay, FACS cell cycle analysis, colony formation assay, and transwell migratory assay. Our results revealed an inverse correlation of expression between miR-143 and KRAS protein in prostate cancer samples (Pearson's correlation scatter plots: R = -0.707, P < 0.05). Moreover, over-expression of miR-143 in prostate cancer cells suppressed their proliferation and migration and increased their sensitivity to docetaxel by targeting EGFR/RAS/MAPK pathway. These findings suggest that miR-143 plays an important role in prostate cancer proliferation, migration and chemosensitivity by suppressing KRAS and subsequent inactivation of MAPK pathway, which provides a potential development of a new approach for the treatment of prostate cancer.
Similar articles
- miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.
Yu J, Lu Y, Cui D, Li E, Zhu Y, Zhao Y, Zhao F, Xia S. Yu J, et al. Oncol Rep. 2014 Feb;31(2):910-8. doi: 10.3892/or.2013.2897. Epub 2013 Dec 5. Oncol Rep. 2014. PMID: 24317363 - miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
Liu Y, Zhang M, Qian J, Bao M, Meng X, Zhang S, Zhang L, Zhao R, Li S, Cao Q, Li P, Ju X, Lu Q, Li J, Shao P, Qin C, Yin C. Liu Y, et al. DNA Cell Biol. 2015 Jun;34(6):429-36. doi: 10.1089/dna.2014.2629. Epub 2015 Mar 26. DNA Cell Biol. 2015. PMID: 25811077 Free PMC article. - MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.
Guo J, Feng Z, Huang Z, Wang H, Lu W. Guo J, et al. Mol Cells. 2014 Sep;37(9):664-71. doi: 10.14348/molcells.2014.0121. Epub 2014 Sep 18. Mol Cells. 2014. PMID: 25234467 Free PMC article. - MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel.
Yang F, Luo LJ, Zhang L, Wang DD, Yang SJ, Ding L, Li J, Chen D, Ma R, Wu JZ, Tang JH. Yang F, et al. Gene. 2017 Feb 5;600:21-28. doi: 10.1016/j.gene.2016.11.037. Epub 2016 Nov 29. Gene. 2017. PMID: 27913185 - Nanoways to overcome docetaxel resistance in prostate cancer.
Ganju A, Yallapu MM, Khan S, Behrman SW, Chauhan SC, Jaggi M. Ganju A, et al. Drug Resist Updat. 2014 Apr;17(1-2):13-23. doi: 10.1016/j.drup.2014.04.001. Epub 2014 Apr 5. Drug Resist Updat. 2014. PMID: 24853766 Free PMC article. Review.
Cited by
- MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer.
Doldi V, El Bezawy R, Zaffaroni N. Doldi V, et al. Cancers (Basel). 2021 May 14;13(10):2380. doi: 10.3390/cancers13102380. Cancers (Basel). 2021. PMID: 34069147 Free PMC article. Review. - Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity.
Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Ochiya T. Hagiwara K, et al. Sci Rep. 2012;2:314. doi: 10.1038/srep00314. Epub 2012 Mar 15. Sci Rep. 2012. PMID: 22423322 Free PMC article. - Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.
Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I, Ning B. Yu D, et al. Sci Rep. 2015 Feb 23;5:8534. doi: 10.1038/srep08534. Sci Rep. 2015. PMID: 25704921 Free PMC article. - Circulating microRNAs in patients with active pulmonary tuberculosis.
Fu Y, Yi Z, Wu X, Li J, Xu F. Fu Y, et al. J Clin Microbiol. 2011 Dec;49(12):4246-51. doi: 10.1128/JCM.05459-11. Epub 2011 Oct 12. J Clin Microbiol. 2011. PMID: 21998423 Free PMC article. - MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers.
Jackson BL, Grabowska A, Ratan HL. Jackson BL, et al. BMC Cancer. 2014 Dec 10;14:930. doi: 10.1186/1471-2407-14-930. BMC Cancer. 2014. PMID: 25496077 Free PMC article. Review.
References
- Genome Res. 2009 Jan;19(1):92-105 - PubMed
- Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1949-54 - PubMed
- Oncol Rep. 2006 Oct;16(4):845-50 - PubMed
- J Biol Chem. 2008 Nov 7;283(45):31079-86 - PubMed
- Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous